Copertina

Sotagliflozin pretreatment attenuates acute LPS-induced depression-like behavioral abnormalities and modulates the gut microbiota-immune-brain axis

Inflammation-driven depression is increasingly recognized as a major therapeutic target, yet effective pharmacological strategies remain limited. Sotagliflozin (SOTA), a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), has demonstrated anti-inflammatory and metabolic benefits, but...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Zeng, Jun (Autore) , Zhou, Lihuimei (Autore) , Liao, Lei (Autore) , Wu, Daobin (Autore) , Yang, Rongying (Autore) , Zhang, Chunda (Autore) , Bai, Zhou (Autore) , Fan, Xinrong (Autore) , Zhou, Xiangyu (Autore) , Zhang, Chunxiang (Autore) , Li, Jiafu (Autore) , Chang, Lijia (Autore) , Wei, Yan (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 07 July 2026
In: Psychopharmacology

ISSN:1432-2072
DOI:10.1007/s00213-026-07127-3
Accesso online:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00213-026-07127-3
Testo
Note sull'autore:Jun Zeng, Lihuimei Zhou, Lei Liao, Daobin Wu, Rongying Yang, Chunda Zhang, Zhou Bai, Xinrong Fan, Xiangyu Zhou, Chunxiang Zhang, Jiafu Li, Lijia Chang, Yan Wei
Descrizione
Riassunto:Inflammation-driven depression is increasingly recognized as a major therapeutic target, yet effective pharmacological strategies remain limited. Sotagliflozin (SOTA), a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2), has demonstrated anti-inflammatory and metabolic benefits, but its neuropsychiatric effects remain unclear.
Descrizione del documento:Gesehen am 04.08.2026
Descrizione fisica:Online Resource
ISSN:1432-2072
DOI:10.1007/s00213-026-07127-3

Documenti analoghi